Here is my understanding of the LymPro testing and

Here is my understanding of the LymPro testing and Partnering process.

A few weeks before the Copenhagen Conference Gerald blogged saying they were "contemplating" delaying reporting on the LP002 test until the 31st. They did delay it, but they only presented a part of that test on the 31st. Another name for that test is the "bridge test." (This has caused some confusion) Gerald blogged after the 31st Conference that we would have the bridge test's complete results in Q3. (Probably late August or early Sept.) He said following that we should get the partnership announcement. That also coincides with the official end of summer. Hopefully, all of that will happen before the shareholder meeting on Sept. 22nd.

Immediately after the partnership announcement, we will begin doing the 12 week validation study in our partner's lab, necessary to finish the Analytical Performance Package so we can begin commercialization. If we get the LymPro partnership in mid September and immediately start this validation study, we can begin commercialization around mid December, as Gerald has promised.

I believe the process will go as I have outlined above. LymPro alone can get us to .30 to 60 cents by December. We can have a reasonable RS in that price range and up list. If things go as I've outlined, I will have no problem voting for the extra billion shares.